ABSTRACT Background/Aims: Silymarin, used by 30 -40% of liver disease patients, is comprised of 6 major flavonolignans each of which may contribute to silymarin's hepatoprotective properties. Previous studies have only described the pharmacokinetics for two flavonolignans, silybin A and silybin B, in healthy volunteers. The aim of this study was to determine the pharmacokinetics of the major silymarin flavonolignans in liver disease patients.
Silymarin, an extract of milk thistle (Silybum marianum), is an herbal medicine that has been used for centuries to self-treat liver disease. High public perception of silymarin's therapeutic benefits is suggested from the use of this complementary alternative medicine by 30-40% of patients with liver disease (Russo et al., 2001) . Silymarin is comprised of six major flavonolignans: silybin A; silybin B; isosilybin A; isosilybin B; silychristin; and silydianin.
Antioxidant (Psotova et al., 2002; Kren et al., 2000) , anti-inflammatory/immunomodulatory (Manna et al., 1999; Schumann et al., 2003) , and anti-fibrotic (Crocenzi et al., 2006) properties of silymarin have been demonstrated in various in vitro and animal models. Whether one or more of these six silymarin flavonolignans are responsible for potentially hepatoprotective effects in patients with liver disease is unknown.
Oxidative stress, inflammation, and fibrosis are characteristics of chronic liver disease, and provide the rationale for investigations on the effect of silymarin on disease progression in the absence of direct antiviral activity. Although silymarin appears to be well tolerated, the therapeutic benefits of silymarin have not been consistently demonstrated in various liver disease populations (Saller et al., 2001; Jacobs et al., 2002; Rambaldi et al., 2007; Mayer et al., 2005) .
For example, changes in standard surrogate clinical endpoints, such as serum alanine aminotransaminase (ALT), have not been observed in patients with chronic hepatitis C and early stage of disease (Buzzelli et al., 1994; Par et al., 2000; Tanamly et al., 2004; Gordon et al., 2006) . Other studies suggest silymarin may have anti-fibrotic activity and may decrease the complications of liver disease and mortality in patients with cirrhotic disease (Ferenci et al., 1989; Pares et al., 1998; Lucena et al., 2002) . In addition, silymarin has been shown to reduce insulin resistance and lipid peroxidation in cirrhotic diabetic patients (Velussi et al., 1997) which are metabolic complications also observed in patients with non-alcoholic steatohepatitis.
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5 However, the use of different silymarin regimens and lack of information on the silymarin exposures attained in these various patient populations make it difficult to draw conclusions on the efficacy of silymarin and on which patient population should be targeted for further clinical investigation.
The pharmacokinetics for only two of the six major silymarin flavonolignans, silybin A and silybin B, have been extensively studied since they are also contained in two phospholipid formulations with better bioavailability, silipide and silybin-phytosome. However, neither of these formulations has been studied in patients with liver disease, while the pharmacokinetics of silymarin has only been described in healthy volunteers (Weyhenmeyer et al., 1992; Rickling et al., 1995; Wen et al., 2008) . Extensive first-pass phase 2 metabolism presumably accounts for the low systemic exposures that have been observed with customary doses of silymarin. For example, plasma AUCs for total flavonolignans (which reflect parent plus conjugated flavonolignans) have been reported to be 3-to 4-fold and 12-to 36-fold higher for silybin A and silybin B, respectively, compared to AUCs for parent flavonolignans (Weyhenmeyer et al., 1992; Rickling et al., 1995; Wen et al., 2008) . Silymarin conjugates likely undergo primarily biliary excretion since only about 5% of the dose is recovered as conjugates in urine (Lorenz et al., 1984; Weyhenmeyer et al., 1992) . Silymarin's disposition may be altered in liver disease since some phase 2 conjugation pathways and transporter proteins that could be involved in the active transport of flavonolignans have been shown to be decreased in patients with liver disease (Congiu et al., 2002; Guardigli et al., 2005; Hinoshita et al., 2001 ). Thus, differences in silymarin's pharmacokinetics and systemic exposures may account for inconsistencies in clinical outcomes that have been observed between patients with mild and cirrhotic liver disease.
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To determine if silymarin's disposition is influenced by the severity or type of liver disease, we conducted a single dose pharmacokinetic study with a standardized milk thistle extract in three patient cohorts that differed by stage and type of liver disease. A healthy volunteer cohort was also included for comparison to patient cohorts and for reference to previous investigations. The pharmacokinetics of six major silymarin flavonolignans and their conjugates were determined and correlated with ALT and with 8-isoprostane F 2α and caspase-3/7 activity, as plasma measures of oxidative stress and apoptosis, respectively. Sulfate and glucuronide conjugate pools for the major silymarin flavonolignans were also examined to gain additional insight on how liver disease might influence silymarin's metabolism and disposition. 
Materials and Methods
Subjects and Study Design. This single-dose, open-label, non-randomized study enrolled 5 subjects into each of the four cohorts (n=20). The primary objective of this study was to determine preliminary point estimates and variance information for the pharmacokinetic parameters AUC, C max , t max , CL/F, and t 1/2 in healthy volunteers and in patients diagnosed with either HCV and minimal liver disease or cirrhosis, or nonalcoholic fatty liver disease (NAFLD) receiving a single 600 mg dose of milk thistle extract. Assuming an absence of disease effects, the selected sample size of N = 5 per each cohort was based on historical experience in healthy subjects and not on statistical considerations. However, an a priori power calculation suggested that a two-sided t-test would have 90% power to detect a 2.5-fold increase in the AUC for total silybin A + silybin B at an α =0.05 using previously reported mean and variance data from healthy volunteers (Weyhenmeyer et al. 1992 ).
Male and female subjects aged 18 to 65 years with a body weight The final patient cohort consisted of NAFLD patients confirmed by a diagnostic biopsy within six months of study participation or by serologies that confirmed the exclusion of other liver diseases. Exclusion criteria included: pregnant or lactating females; other active liver diseases; HIV co-infection; history of pancreatic or biliary disease; acute illness that would interfere with drug absorption; allergy or hypersensitivity reaction to milk thistle or any of its components; use of any silymarin-containing product within 30 days prior to enrollment; or use of alcohol within The specific flavonolignan content of this milk thistle extract has been previously determined by our laboratory (Wen et al., 2008) as follows: 37.7 mg, silybin A; 58.8 mg, silybin B; 14.8 mg, isosilybin A; 6.3 mg, isosilybin B; 39.2 mg, silychristin; and 15.3 mg, silydianin. Therefore, DMD#19604 9 these six flavonolignans account for 172 mg, or 57%, of the 300 mg milk thistle extract contained in each capsule (Wen et al., 2008) . MS analysis and detection were conducted using an API 100 LC/MS system (PerkinElmer Sciex, Toronto, Canada) with a TurboIonspray interface in the negative ESI ionization mode. The limit of detection and linear quantitative range for the six silymarin flavonolignans were 2-1000 ng/ml and 5-1000 ng/ml, respectively. Intra-and inter-day precisions were 1.7 -11%, and 4.5 -14%, respectively. For authentic reference standards, the composition of silybin (Silibinin, SigmaAldrich, St. Louis, MO) was confirmed to be a mixture of silybin A (SA) and silybin B (SB) by LC-ESI-MS and the specific contents of SA and SB were analyzed to be 48% and 52%, respectively. Silychristin (SC) was obtained from ChromaDex (Santa Ana, CA), and silydianin (CrCl >60 ml/min) for all study subjects.
Pharmacokinetics of Parent Silymarin Flavonolignans.
The plasma C max and AUC 0-24h for six major silymarin flavonolignans are presented in Table 2 . Silybin A and silybin B were the main flavonolignans in the plasma for all cohorts and their C max ranged from 12 ng/ml (healthy) up to 69 ng/ml (HCV cirrhosis), and from 9 ng/ml (healthy) up to 40 ng/ml (NAFLD), respectively. Silybin A and silybin B exposures (AUC 0-24h ) were also higher in patient cohorts compared to the healthy cohort. C max and AUC 0-24h for the other silymarin flavonolignans (ISA, ISB, SC, and SD) were only consistently quantifiable in the liver disease cohorts. The HCV cirrhosis cohort had the highest AUC 0-24h for all silymarin flavonolignans. Absorption from the gastrointestinal tract was rapid for all cohorts as indicated by a median T max between 0.5 to 2 hours for the various flavonolignans. By 6 hours post-dose, flavonolignan concentrations had fallen below the detection limit in a majority of subjects due to short elimination half-lives (0.6 to 1.6 hours) for the silymarin flavonolignans observed in all cohorts (data not shown).
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The apparent clearances for the six major silymarin flavonolignans have not been previously reported and are also presented in Table 2 . CL/F's for silybin A and silybin B were between 27 -48% and 33 -51% lower, respectively, in the HCV cohorts compared to the healthy cohort. However, these differences were not detected as significant due to large inter-subject variability. CL/F for the NAFLD cohort was comparable to the healthy cohort.
These data suggest that both liver disease etiology and disease stage may be associated with decreases in the clearance of parent silymarin flavonolignans that may result in increased exposures compared to those observed in healthy volunteers.
Pharmacokinetics of Total Silymarin Flavonolignans. Table 3 depicts the plasma C max and AUC 0-24h for the total (parent + conjugates) concentration of each silymarin flavonolignan, which were determined following complete enzymatic hydrolysis of conjugates (sulfates and glucuronides) as described in Materials and Methods. C max and AUC 0-24h for the total concentration of each silymarin flavonolignan were increased by similar extents (1.8-to 6.3-fold and 1.2-to 9.9-fold, respectively) in patient cohorts compared to healthy volunteers. The highest exposures were observed for silybin B, isosilybin A, and silychristin across all disease cohorts, and were highest in the HCV cirrhosis cohort (p≤0.02). To determine exposures to the total amount of the six silymarin flavonolignans in blood for each cohort, AUC 0-24h for the total concentration of each flavonolignan were summed and evaluated across the four cohorts. AUC 0-24h for the sum of total silymarin flavonolignans were 2.4-, 3.3-, and 4.7-fold higher for the HCV noncirrhosis, NAFLD (p≤0.03), and HCV cirrhosis (p≤0.03) cohorts, respectively, compared to healthy volunteers (AUC 0-24h =2021 ng*h/ml). Table 3 .
Pharmacokinetics of Silymarin Flavonolignan Conjugates.
To more clearly determine the influence of disease type and severity on the disposition of silymarin conjugates, a "conjugate pool" concentration was calculated at each time point for all cohorts. First, the conjugate (sulfates + glucuronides) concentrations for each silymarin flavonolignan were obtained from the difference between parent (Table 2 ) and total (Table 3 ) plasma concentrations. Then the conjugate concentrations for all six silymarin flavonolignans were summed to obtain a "Sum silymarin conjugates" concentration. Figure 2 depicts for each cohort, the concentration versus time profiles for Sum silymarin conjugates expressed in terms of "Parent Flavonolignan
Equivalents". These concentration data were used to determine the Sum silymarin conjugates AUC 0-24h which are also depicted in Figure 2 (see Table inset ). Compared to healthy volunteers, Sum silymarin conjugates AUC 0-24h were 2.4-, 3.3-, and 4.7-fold greater in HCV noncirrhosis, NAFLD, and HCV cirrhosis cohorts, respectively. The Sum silymarin conjugates C max (data not DMD#19604 15 shown) and AUC 0-24h were significantly elevated in the NAFLD and HCV cirrhosis cohorts compared to the healthy cohort (p≤0.03). These increases in Sum silymarin conjugates AUC 0-24h are similar to the increases observed for the sum of total silymarin flavonolignans AUC 0-24h since flavonolignan conjugates account for 97 -99% of total flavonolignan concentrations. The elimination half-life for patient cohorts ranged from 8 to 10 hours compared to 4 hours for the healthy cohort. Although the 24 hour sampling interval did not allow precise estimates of the terminal elimination phase, these data suggest that the elimination of silymarin conjugates is more prolonged in liver disease.
Silymarin Flavonolignan Metabolism. Figure 3 depicts the relative proportions of glucuronide conjugates for silybin B and isosilybin A, which were between 77 -86% and 14 -23%, respectively, across all cohorts. While the primary route of metabolism was glucuronidation for silybin B, and sulfation for isosilybin A, there were no significant effects of disease severity or type on the extent of their conjugation. These data indicate that the higher silymarin flavonolignan conjugate exposures observed in patient cohorts did not reflect alterations in preferred pathways of phase 2 metabolism.
Measures of Disease Activity. To determine if changes in Sum silymarin conjugates AUC 0-24h
were associated with various measures of liver disease activity, the Sum silymarin conjugates AUC 0-24h was correlated with measures of oxidative stress and apoptosis in plasma for each of the twenty subjects. As seen in Figure 4 , the Sum silymarin conjugates AUC 0-24h correlated with plasma caspase-3/7 activity (R 2 =0.52, p<0.001), a measure of apoptosis. Compared to healthy volunteers, plasma caspase-3/7 activity was 1.3-, 1.1-, and 4.7-fold higher in HCV noncirrhosis,
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16 NAFLD, and HCV cirrhosis (p≤0.005) cohorts, respectively. In contrast, no correlations were observed with plasma concentrations of either 8-isoprostane F 2α (Figure 3 inset) , a biomarker of oxidative stress, or between IL-6 or ALT across all patients, and significant differences between cohorts were not detected (data not shown).
Discussion
Single daily doses of silymarin up to 1260 mg per day (Gordon et al., 2006; Huber et al., 2005 ) have only been studied in patients with early stage liver disease while other trials in patients with advanced disease have utilized three times daily doses of 140 or 150 mg (Ferenci et al., 1989; Pares et al., 1998; Lucena et al., 2002) . Previous clinical trials have failed to include measures of silymarin exposure and the inconsistent reports of silymarin's clinical benefits may reflect variation in the exposures attained due to either the effects of liver disease on silymarin's pharmacokinetics, or the different dosing regimens utilized. This is the first investigation of the pharmacokinetics of the six major silymarin flavonolignans and their conjugates in patients with different types and stages of liver disease. Exposures for parent silymarin flavonolignans were generally higher in patient cohorts, especially for isosilybin A, isosilybin B, and silychristin which were not detected in healthy volunteers. However, these exposures were not maintained past six hours post-dose due to low C max concentrations and short half-lives. These data suggest that the silymarin dosing regimens currently used by patients to self-treat their liver disease, or previously evaluated in clinical trials, may not provide adequate plasma exposures to obtain the antioxidant, anti-inflammatory, or anti-fibrotic benefits of silymarin.
Previous silymarin pharmacokinetic studies in healthy subjects have underestimated total silymarin exposures since they have only focused on silybin A and silybin B, which are the major silymarin flavonolignans in milk thistle extracts. Silybin A and silybin B comprised 56% of the flavonolignans in the milk thistle extract used in this study (Wen et al., 2008) but they accounted for only 43% of the sum of total silymarin flavonolignans exposure in healthy volunteers. In patients with liver disease, silybin A and silybin B accounted for even less of the sum of total silymarin flavonolignans (31 -38%) due the accumulation of silychristin which DMD#19604 18 accounted for 18% in healthy subjects and 20 -36% in patients with liver disease. All of the silymarin flavonolignans have been shown to have potent antioxidant activity (Psotova et al., 2002; Kvasnicka et al., 2003) , and therefore they may contribute significantly to the clinical effects of silymarin in patients with liver disease.
The increases in peak plasma concentrations and exposures for parent silymarin flavonolignans in patients with liver disease most likely reflect increased intestinal absorption by the gastrointestinal tract and not decreased phase 2 conjugation by either the gut or liver since total silymarin conjugates were also increased. Hepatic and gastrointestinal tissues share many of the same drug transporters that are involved in the absorption of flavonolignans (Morris and Zhang, 2006; Cermak and Wolffran, 2006) , and biliary obstruction results in changes in transporter expression in both rat liver and intestine (Kamisako and Ogawa, 2007) . Since hepatic expression of many of these drug transporters may be down-regulated in chronic HCV (Hinoshita et al., 2001) , the increased absorption of silymarin flavonolignans may reflect a similar down-regulation of transporters within the gastrointestinal tract, such as multidrug resistance protein 2 (MRP2), that might normally limit the absorption of silymarin flavonolignans.
In our study, the most significant alteration in the disposition of silymarin in patients with liver disease was reflected in the plasma concentrations for the sum of total silymarin flavonolignans where exposures were 2.4-to 4.7-fold higher in patient cohorts compared to healthy volunteers. The difference in the mean age between the healthy cohort (30 ± 17 years) and liver disease cohorts (e.g. 53 ± 4 years HCV cirrhosis) may be a limitation to our study because of the potential for age-related differences in metabolism. However, it is unlikely that the 2.4-to 4.7-fold differences in silymarin exposures between liver disease cohorts and healthy DMD#19604 19 volunteers can be explained by age differences since ages overlap between cohorts and significant influences of age on the disposition of drugs that primarily undergo high first-pass, phase 2 metabolism by the glucuronosyl transferase system have not been observed.
The extent of phase 2 conjugation by either glucuronidation or sulfation pathways for silybin B and isosilybin A was unaffected by liver disease stage or type. Therefore, the elevated plasma levels of phase 2 conjugates of silymarin may result primarily from alterations in hepatic excretion processes rather than from increased phase 2 metabolism. Similar increases in flavonolignan exposures have been reported in a rat model of cirrhosis where an approximately 2-fold increase in plasma AUC for silybin A and B conjugates was correlated with a 50% reduction in the bile to blood exposure ratio for silybin A and B conjugates in cirrhotic rats compared to control (Wu et al., 2008) . In humans, decreased biliary excretion of flavonolignan conjugates may potentially influence the efficacy of silymarin due to reduced enterohepatic recycling and return of parent flavonolignans via portal blood. In addition, different types of liver disease or liver injury have been shown to induce different changes in the expression of hepatic transporters in humans (Barnes et al., 2007) and in animal models (Lickteig et al., 2006) .
Our data suggest that one measure of liver disease activity, a simple biochemical assay of caspase-3/7 activity in blood, may be useful for predicting the disposition of drugs that undergo extensive conjugation and biliary elimination like silymarin in patients with liver disease. In chronic HCV patients, apoptosis and serum caspase-3/7 activity correlate with liver disease grade and stage (Seidel et al., 2005; Calabrese et al., 2000; Bantel et al., 2001; Bantel et al., 2004) . Caspase-3/7 activity reflects the net contributions of several activators of apoptosis because of their downstream location in both the intrinsic and extrinsic pathways of apoptosis.
In contrast to caspase-3/7 activity, plasma levels of 8-isoprostane F 2α , IL-6, and serum ALT DMD#19604 20 values did not correlate with AUC 0-24h for Sum silymarin conjugates. Altered hepatic expression of biliary transporters was shown to be independent of the inflammation and oxidative stress associated with bile duct-ligation (Wagner et al., 2005) . Therefore, other components of disease activity, perhaps related to the development of cirrhosis, may account for the association between caspase-3/7 activity and altered disposition of silymarin conjugates which was most apparent in the HCV cirrhotic cohort. Alternatively, hepatocytes undergoing apoptosis may represent that fraction of the liver with decreased ability to eliminate conjugates of silymarin flavonolignans.
It is not known whether parent or conjugated silymarin flavonolignans are responsible for silymarin's purported therapeutic effects since both silybin and its 7-glucuronide conjugate have demonstrated antioxidant activity in vitro at a concentration of 330 µ M (Kren et al., 2000) .
Recently, the anti-viral activity of a standardized silymarin extract was demonstrated in an in vitro cell culture model of HCV replication at concentrations ranging between 20 µ M -40 µ M (Polyak et al., 2007) . In our study, the peak plasma concentration for all silymarin flavonolignans combined only amounted to 0.5 µ M (225 ng/ml) for HCV patients with cirrhosis, who achieved the highest levels of exposure following a customary dose of silymarin.
Therefore, customary doses of silymarin are not likely to achieve the plasma concentrations required for the antioxidant and antiviral effects of silymarin.
Silymarin exposures have been underestimated in previous studies because of their failure to quantitate the six major silymarin flavonolignans. Therefore, future clinical investigations should be directed towards an evaluation of the independent roles of the major silymarin flavonolignans and their conjugates to determine their effects in various liver disease populations. However, before such studies are undertaken, pharmacokinetic studies that examine DMD#19604 21 higher, multiple daily silymarin dose regimens in patients with liver disease are needed to identify regimens that provide optimal 24 hour exposures. To this end, a Phase I double-blind, randomized clinical trial has been undertaken to evaluate the safety, tolerability, and pharmacokinetics of silymarin in a dose escalation manner in both non-cirrhotic HCV and NAFLD patients. Caspase 3/7 activity correlated with Sum silymarin conjugates AUC 0-24h (R 2 =0.52, p<0.001).
Plasma 8-isoprostane F 2α did not correlate with Sum silymarin conjugates AUC 0-24h (R 2 =0.01, p>0.9), see Figure inset . RLU, relative light units. Data are presented as mean values ± standard deviation unless otherwise specified.
BMI, body mass index.
